C.R.S. Section 10-3-803.5
Acquisitions involving insurers not otherwise covered

  • definitions

(1)

As used in this section, unless the context otherwise requires:

(a)

“Acquisition” means an agreement, arrangement, or activity the consummation of which results in a person acquiring directly or indirectly the control of another person, and includes the acquisition of voting securities, the acquisition of assets, bulk reinsurance, and mergers.

(b)

For the purposes of subparagraph (IV) of paragraph (b) of subsection (2) of this section, “insurer” includes any company or group of companies under common management, ownership, or control.

(c)

“Involved insurer” includes an insurer that either acquires or is acquired through an acquisition, is affiliated with an insurer that acquires or is acquired through an acquisition, or is the result of a merger.

(d)

“Market” means:

(I)

For the purposes of subparagraph (IV) of paragraph (b) of subsection (2) of this section, direct written insurance premium in this state for a line of business as contained in the annual statement required to be filed by insurers licensed to do business in this state;

(II)

For the purposes of paragraph (b) of subsection (4) of this section, the relevant product and geographical markets. In determining the relevant product and geographical markets, the commissioner shall give due consideration to, among other things, the definitions or guidelines, if any, promulgated by the NAIC and to information, if any, submitted by parties to the acquisition. In the absence of sufficient information to the contrary, the relevant product market is assumed to be the direct written insurance premium for a line of business, such line being that used in the annual statement required to be filed by insurers doing business in this state, and the relevant geographical market is assumed to be this state.

(2)

Scope.

(a)

Except as exempted in paragraph (b) of this subsection (2), this section applies to any acquisition in which there is a change in control of an insurer authorized to do business in this state.

(b)

This section does not apply to the following:

(I)

A purchase of securities solely for investment purposes if the securities are not used by voting or otherwise to cause or attempt to cause the substantial lessening of competition in any insurance market in this state. If a purchase of securities results in a presumption of control under section 10-3-801 (3), the purchase is not solely for investment purposes unless the insurance commissioner of the insurer’s state of domicile accepts a disclaimer of control or affirmatively finds that control does not exist and the disclaimer action or affirmative finding is communicated by the domiciliary commissioner to the commissioner of this state.

(II)

The acquisition of a person by another person when both persons are neither directly nor through affiliates primarily engaged in the business of insurance, if preacquisition notification is filed with the commissioner in accordance with paragraph (b) of subsection (3) of this section thirty days before the proposed effective date of the acquisition; except that preacquisition notification is not required for exclusion from this section if the acquisition would otherwise be excluded from this section by any other subparagraph of this paragraph (b);

(III)

The acquisition of already affiliated persons;

(IV)

An acquisition if, as an immediate result of the acquisition:

(A)

In no market would the combined market share of the involved insurers exceed five percent of the total market;

(B)

There would be no increase in any market share; or

(C)

In no market would the combined market share of the involved insurers exceed twelve percent of the total market and the combined market share increase by more than two percent of the total market;

(V)

An acquisition for which a preacquisition notification would be required pursuant to this section due solely to the resulting effect on the ocean marine insurance line of business; or

(VI)

An acquisition of an insurer whose domiciliary insurance commissioner affirmatively finds that the insurer is in failing condition; there is a lack of feasible alternatives to improving its condition; the public benefits of improving the insurer’s condition through the acquisition exceed the public benefits that would arise from not lessening competition; and the findings are communicated by the domiciliary commissioner to the commissioner of this state.

(3)

Intentionally left blank —Ed.

(a)

An acquisition covered by subsection (2) of this section may be subject to an order pursuant to subsection (5) of this section unless the acquiring person files a preacquisition notification and the waiting period has expired. The acquired person may file a preacquisition notification. The commissioner shall give confidential treatment to information submitted under this subsection (3) in the same manner as otherwise provided in this part 8; except that the notice required by subsection (3)(d)(I) of this section must include the information specified in subsection (3)(d)(I) of this section if the preacquisition notification presents prima facie evidence of a violation of the competitive standard specified in subsection (4)(b) of this section.

(b)

The preacquisition notification must be in the form and contain the information as prescribed by the NAIC relating to those markets which, under subparagraph (IV) of paragraph (b) of subsection (2) of this section, cause the acquisition not to be exempted from this section. The commissioner may require additional material and information as deemed necessary to determine whether the proposed acquisition, if consummated, would violate the competitive standard of subsection (4) of this section. The required information may include an opinion of an economist as to the competitive impact of the acquisition in this state accompanied by a summary of the education and experience of the economist indicating his or her ability to render an informed opinion.

(c)

Except as otherwise provided in subsection (3)(d) of this section:

(I)

The waiting period begins on the date of receipt by the commissioner of a preacquisition notification and ends on the earlier of the thirtieth day after the date of receipt or termination of the waiting period by the commissioner; and

(II)

Before the end of the waiting period, the commissioner, on a one-time basis, may require the submission of additional needed information relevant to the proposed acquisition, in which event the waiting period ends on the earlier of the thirtieth day after receipt of the additional information by the commissioner or termination of the waiting period by the commissioner.

(d)

If the proposed acquisition involves one or more health insurers:

(I)

The commissioner shall provide public notice of the filing of an application for an acquisition of control referred to in subsection (2)(a) of this section no later than five business days after the receipt of the preacquisition notification required by subsection (3)(a) of this section. If the preacquisition notification presents prima facie evidence of a violation of the competitive standard specified in subsection (4)(b) of this section, the notice must include:

(A)

The relevant product for which prima facie evidence of the violation of the competitive standard was presented in the preacquisition notice;

(B)

The relevant geographic market for which prima facie evidence of the violation of the competitive standard was presented in the preacquisition notice; and

(C)

As specified in subsection (4)(b)(I)(A) or (4)(b)(I)(B) of this section, the shares of the market in which prima facie evidence of the violation of the competitive standard was presented in the preacquisition notice.

(II)

The commissioner shall review the impact of a proposed acquisition on competition when the proposed acquisition involves a transaction that the commissioner determines would present prima facie evidence of a violation of the competitive standard specified in subsection (4) of this section. The review must include a public hearing or an opportunity for the public to submit written comments to the commissioner.

(III)

The waiting period begins on the date of receipt by the commissioner of a preacquisition notification and, except as specified in subsection (3)(d)(IV) of this section, ends on the earlier of the thirtieth day after the date of receipt of the preacquisition notification or termination of the waiting period by the commissioner.

(IV)

If the commissioner allows for public comment as part of the review of a merger, the waiting period ends on the earlier of the thirtieth day after the date of receipt of the preacquisition notification or termination of the waiting period by the commissioner. If the commissioner holds a hearing as part of the review of a merger, the waiting period ends on the date of the hearing.

(V)

Before the end of the waiting period, the commissioner, on a one-time basis, may require the submission of additional needed information relevant to the proposed acquisition.

(VI)

Nothing in this section prevents an applicant from making the preacquisition notification available for confidential stakeholder inspection.

(4)

Competitive standard.

(a)

The commissioner may enter an order under paragraph (a) of subsection (5) of this section with respect to an acquisition if:

(I)

There is substantial evidence that the effect of the acquisition may be substantially to lessen competition in any line of insurance in this state or tend to create a monopoly; or

(II)

The insurer fails to file adequate information in compliance with subsection (3) of this section.

(b)

In determining whether a proposed acquisition would violate the competitive standard of paragraph (a) of this subsection (4), the commissioner shall consider the following:

(I)

An acquisition covered under section 10-3-803 (2) involving two or more insurers competing in the same market is prima facie evidence of violation of the competitive standards if one of the following occurs:

(A)

The market is highly concentrated and the involved insurers possess the following shares of the market:
Insurer A
Insurer B
4%
4% or more
10%
2% or more
15%
1% or more

(B)

The market is not highly concentrated and the involved insurers possess the following shares of the market:
Insurer A
Insurer B
5%
5% or more
10%
4% or more
15%
3% or more
19%
1% or more

(II)

A highly concentrated market is one in which the share of the four largest insurers is seventy-five percent or more of the market. Percentages not shown in the tables of sub-subparagraphs (A) and (B) of subparagraph (I) of this paragraph (b) are interpolated proportionately to the percentages that are shown. For the purpose of subparagraph (I) of this paragraph (b), the insurer with the largest share of the market is deemed to be insurer A.

(III)

Whether there is a significant trend toward increased concentration in the market. There is a significant trend toward increased concentration in the market when the aggregate market share of any grouping of the largest insurers in the market, from the two largest to the eight largest, has increased by seven percent or more of the market over a period of time extending from any base year five to ten years prior to the acquisition up to the time of the acquisition. An acquisition covered under subsection (2) of this section involving two or more insurers competing in the same market is prima facie evidence of violation of the competitive standard in paragraph (a) of this subsection (4) if:

(A)

There is a significant trend toward increased concentration in the market;

(B)

One of the insurers involved is one of the insurers in a grouping of large insurers showing the requisite increase in the market share; and

(C)

Another involved insurer’s market is two percent or more; and

(IV)

Even though an acquisition is not prima facie violative of the competitive standard under subparagraph (I) or (III) of this paragraph (b), the commissioner may establish the requisite anticompetitive effect based upon other substantial evidence. Even though an acquisition is prima facie violative of the competitive standard under subparagraph (I) or (III) of this paragraph (b), a party may establish the absence of the requisite anticompetitive effect based upon other substantial evidence. Relevant factors in making a determination under this subparagraph (IV) include the following: Market shares, volatility of ranking of market leaders, number of competitors, concentration, trend of concentration in the industry, and ease of entry and exit into the market.

(c)

The burden of showing prima facie evidence of violation of the competitive standard rests upon the commissioner.

(d)

The commissioner shall not enter an order under paragraph (a) of subsection (5) of this section if the acquisition will:

(I)

Yield substantial economies of scale or economies in resource utilization that cannot be feasibly achieved in any other way and the public benefits that would arise from such economies exceed the public benefits that would arise from not lessening competition; or

(II)

Substantially increase the availability of insurance and the public benefits of the increase exceed the public benefits that would arise from not lessening competition.

(5)

Orders and penalties.

(a)

Intentionally left blank —Ed.

(I)

If an acquisition violates the standards of this section, the commissioner may enter an order:

(A)

Requiring an involved insurer to cease and desist from doing business in this state with respect to the line or lines of insurance involved in the violation; or

(B)

Denying the application of an acquired or acquiring insurer for a license to do business in this state.

(II)

The commissioner shall not enter an order under this paragraph (a) unless:

(A)

There is a hearing on the proposed order;

(B)

Except for a hearing held pursuant to subsection (3)(d) of this section, notice of the hearing is issued before the end of the waiting period and not less than fifteen days before the hearing;

(C)

For a hearing held pursuant to subsection (3)(d) of this section, notice of the hearing is issued by the later of the thirtieth day after receipt by the commissioner of a preacquisition notification or by the date the commissioner sets for the receipt of public comments;

(D)

Except for a hearing held pursuant to subsection (3)(d) of this section, the hearing is concluded and the order is issued no later than sixty days after the date of the filing of the preacquisition notification with the commissioner; and

(E)

For a hearing held pursuant to subsection (3)(d) of this section, the hearing is concluded and the order is issued no later than sixty days after the end of the waiting period.

(III)

Every order must be accompanied by a written decision of the commissioner setting forth findings of fact and conclusions of law.

(IV)

An order entered pursuant to this paragraph (a) does not apply if the acquisition is not consummated.

(b)

A person who violates a cease-and-desist order of the commissioner under paragraph (a) of this subsection (5) and while the order is in effect is, after notice and hearing and upon order of the commissioner, subject at the discretion of the commissioner to one or more of the following:

(I)

A monetary penalty of not more than ten thousand dollars for every day of violation; or

(II)

Suspension or revocation of the person’s license.

(c)

An insurer or other person who fails to make any filing required by this section, and who also fails to demonstrate a good-faith effort to comply with any filing requirement, is subject to a fine of not more than fifty thousand dollars.

(6)

Sections 10-3-810 (2) and (3) and 10-3-812 do not apply to acquisitions covered under subsection (2) of this section.

Source: Section 10-3-803.5 — Acquisitions involving insurers not otherwise covered - definitions, https://leg.­colorado.­gov/sites/default/files/images/olls/crs2023-title-10.­pdf (accessed Oct. 20, 2023).

10‑3‑101
Formation of insurance companies 10‑3‑102
Purpose of organization or admittance 10‑3‑103
Names of companies 10‑3‑104
Unauthorized companies - penalties 10‑3‑105
Certificate of authority to do business - companies prohibited - definitions 10‑3‑106
Deemed incorporated under corporation law 10‑3‑107
Appointment of registered agent to receive service of process - commissioner required to maintain list - when service of process may be made on commissioner 10‑3‑108
File duly certified copy of charter 10‑3‑109
Reports, statements, assessments, and maintenance of records - publication - penalties for late filing, late payment, or failure to maintain 10‑3‑111
Violations - penalty 10‑3‑112
Directors - terms - election - conflicts of interest - recovery of profits 10‑3‑113
Increase of capital 10‑3‑114
Violations - penalty 10‑3‑117
License automatically extended - when 10‑3‑120
Investments of officers, directors, and principal stockholders 10‑3‑121
Regulation of proxies, consents, or authorizations 10‑3‑122
Duties of foreign companies 10‑3‑123
Assessment accident associations 10‑3‑125
Redomestication of foreign insurers 10‑3‑126
Alien insurers 10‑3‑127
Domicile of nonprofit hospital, medical-surgical, and health services corporations 10‑3‑128
Domestic insurer - requirement to maintain offices in this state 10‑3‑129
Prohibition - display of social security number - insurance companies 10‑3‑130
Certificate of authority application process - tracking compliance with uniform process 10‑3‑131
Acts of producers - responsibility of insurer - definitions 10‑3‑201
Cash capital - guaranty fund - deposit 10‑3‑202
Surplus ascertained - disposition of 10‑3‑203
Additional deposits - withdrawals 10‑3‑204
Payment of dividends 10‑3‑205
Manner of paying surplus 10‑3‑206
Security deposits - certificates 10‑3‑207
Fees paid by insurance companies 10‑3‑208
Financial statements 10‑3‑209
Tax on premiums collected - exemptions - penalties 10‑3‑210
Deposit and safekeeping of securities 10‑3‑211
Deposit only admitted assets 10‑3‑212
Insolvency or impairment of stock insurance company 10‑3‑213
Investments eligible as admitted assets 10‑3‑214
Quantitative investment limitations - manner of applying 10‑3‑215
Evidences of indebtedness 10‑3‑215.5
Investments in medium- and lower-grade obligations 10‑3‑216
Mortgage loans 10‑3‑217
Federally guaranteed or insured real estate loans 10‑3‑218
Real estate for use in company’s business 10‑3‑219
Real estate acquired in satisfaction of indebtedness 10‑3‑220
Real estate for production of income - definition 10‑3‑225
Transportation equipment interests 10‑3‑226
Equity interests - definition 10‑3‑227
Stock for purpose of reinsurance, consolidation, or merger 10‑3‑228
Collateral loans 10‑3‑228.5
Securities lending - repurchase - reverse repurchase - dollar roll transactions 10‑3‑229
Investments for purposes of compliance in other jurisdictions 10‑3‑230
Additional investments 10‑3‑231
Valuation of investments 10‑3‑232
Liens for certain purposes permitted 10‑3‑233
Disposition of certain real estate 10‑3‑234
Approval and record of investments 10‑3‑235
Certain admitted assets deemed securities for deposit purposes 10‑3‑236
Assets acquired through merger, consolidation, or reinsurance 10‑3‑237
Assets acquired under prior law 10‑3‑238
Refunds 10‑3‑239
Subordinated indebtedness 10‑3‑240
Approval of investments 10‑3‑242
Qualified money market funds - definition 10‑3‑243
Derivative transactions - definitions - restrictions - rules 10‑3‑244
Climate risk disclosure - insurer participation - rules - reporting - definition 10‑3‑301
Definitions 10‑3‑302
Deposits required - when 10‑3‑303
Deposits with commissioner 10‑3‑304
Depositaries - responsibility 10‑3‑305
Rights of depositors 10‑3‑306
Release of deposits 10‑3‑307
Commissioner order release 10‑3‑401
Legislative declaration 10‑3‑402
Definitions 10‑3‑403
Scope of part 4 10‑3‑404
Determination of delinquency - procedure 10‑3‑405
Direct supervision 10‑3‑406
Protest of finding of delinquency 10‑3‑407
Costs of direct supervision 10‑3‑411
Penalties for noncompliance 10‑3‑412
Review of action while under direct supervision 10‑3‑413
Appeal from final determination or order of commissioner 10‑3‑414
Nondisclosure of reports and evidence during period of direct supervision or conservatorship 10‑3‑501
Legislative declaration - intents and purposes 10‑3‑502
Definitions 10‑3‑503
Persons covered 10‑3‑504
Jurisdiction - venue 10‑3‑504.5
Application for receivership - penalty 10‑3‑505
Injunctions - orders 10‑3‑506
Cooperation of officers, owners, and employees 10‑3‑507
Continuation of delinquency proceedings 10‑3‑508
Condition on release from delinquency proceedings 10‑3‑509
Court’s seizure order 10‑3‑510
Confidentiality of hearings 10‑3‑511
Grounds for rehabilitation 10‑3‑512
Rehabilitation orders 10‑3‑513
Powers and duties of rehabilitator 10‑3‑514
Actions by and against rehabilitator 10‑3‑514.5
Immunity and indemnification of receiver and employees - applicability 10‑3‑515
Termination of rehabilitation 10‑3‑516
Grounds for liquidation 10‑3‑517
Liquidation orders 10‑3‑518
Continuation of coverage 10‑3‑519
Dissolution of insurer 10‑3‑520
Powers of liquidator 10‑3‑521
Notice to creditors and others 10‑3‑522
Duties of agents 10‑3‑523
Actions by and against liquidator 10‑3‑524
Collection and listing of assets 10‑3‑525
Fraudulent transfers prior to petition 10‑3‑526
Fraudulent transfer after petition 10‑3‑527
Voidable preferences and liens 10‑3‑528
Claims of holders of void or voidable rights 10‑3‑529
Setoffs - effective date - applicability 10‑3‑530
Assessments 10‑3‑531
Reinsurers’ liability 10‑3‑532
Recovery of premiums owed 10‑3‑533
Domiciliary liquidator’s proposal to distribute assets 10‑3‑533.5
Sale of insolvent insurer as a going concern 10‑3‑534
Filing of claims 10‑3‑535
Proof of claim 10‑3‑536
Special claims 10‑3‑537
Special provisions for third-party claims 10‑3‑538
Disputed claims 10‑3‑539
Claims of surety 10‑3‑540
Secured creditors’ claims 10‑3‑540.5
Qualified financial contracts - definitions 10‑3‑541
Priority of distribution - definitions - repeal 10‑3‑542
Liquidator’s recommendations to the court 10‑3‑543
Distribution of assets 10‑3‑544
Unclaimed and withheld funds 10‑3‑545
Termination of proceedings 10‑3‑546
Reopening liquidation 10‑3‑547
Disposition of records during and after termination of liquidation 10‑3‑548
External audit of receiver’s books 10‑3‑549
Conservation of property of foreign or alien insurers found in this state 10‑3‑550
Liquidation of property of foreign or alien insurers found in this state 10‑3‑551
Domiciliary liquidators in other states 10‑3‑552
Ancillary formal proceedings 10‑3‑553
Ancillary summary proceedings 10‑3‑554
Claims of nonresidents against insurers domiciled in this state 10‑3‑555
Claims of residents against insurers domiciled in reciprocal states 10‑3‑556
Attachment, garnishment, and levy of execution 10‑3‑557
Interstate priorities 10‑3‑558
Subordination of claims for noncooperation 10‑3‑559
Severability 10‑3‑601
Short title 10‑3‑602
Exchange of securities 10‑3‑603
Acquiring corporation - definition 10‑3‑604
Procedure for exchange 10‑3‑605
Filing plan of exchange 10‑3‑606
Effect of exchange 10‑3‑607
Authorized insurance business and regulatory authority 10‑3‑608
Domestic company and acquiring corporation separate and distinct entities 10‑3‑609
Examination 10‑3‑610
Application of this part 6 10‑3‑701
Purpose 10‑3‑702
Credit allowed to a domestic ceding insurer - rules - definitions 10‑3‑703
Asset or reduction from liability for reinsurance ceded by a domestic insurer to an assuming insurer not meeting the requirements of section 10-3-702 10‑3‑704
Qualified United States financial institutions 10‑3‑705
Rules 10‑3‑706
Reinsurance agreements affected 10‑3‑801
Definitions 10‑3‑802
Subsidiaries of insurers 10‑3‑803
Acquisition of control of or merger with domestic insurer - definitions 10‑3‑803.5
Acquisitions involving insurers not otherwise covered - definitions 10‑3‑804
Registration of insurers 10‑3‑805
Standards and management of an insurer within an insurance holding company system 10‑3‑806
Examination 10‑3‑807
Supervisory colleges 10‑3‑807.5
Group-wide supervision of internationally active insurance groups - information collection - cooperation - rules 10‑3‑808
Confidential treatment 10‑3‑809
Rules 10‑3‑810
Injunctions - prohibitions against voting securities - sequestration of voting securities 10‑3‑811
Criminal proceedings - civil penalties - definition 10‑3‑812
Receivership 10‑3‑813
Revocation, suspension, or nonrenewal of insurer’s license 10‑3‑814
Judicial review - mandamus 10‑3‑815
Recovery of distributions or payments 10‑3‑816
Conflict with other laws 10‑3‑901
Short title 10‑3‑902
Legislative declaration 10‑3‑903
Definition of transacting insurance business 10‑3‑903.5
Jurisdiction over providers of health-care benefits - rules 10‑3‑904
Commissioner may enjoin unauthorized company 10‑3‑904.5
Emergency cease-and-desist orders - issuance - rules - definition 10‑3‑904.6
Emergency cease-and-desist orders - hearings - judicial review - violations 10‑3‑904.7
Failure to pay penalties or restitution 10‑3‑905
Service of process upon unauthorized company 10‑3‑906
Validity of insurance contracts - liability under insurance contract 10‑3‑907
Investigation and disclosure of insurance contracts 10‑3‑908
Reporting of unauthorized insurance 10‑3‑909
Unauthorized insurance premium tax 10‑3‑910
Application of this part 9 10‑3‑1001
Short title 10‑3‑1002
Legislative declaration 10‑3‑1003
Service of process upon unauthorized insurer 10‑3‑1004
Defense of action by unauthorized insurer 10‑3‑1005
Attorney fees 10‑3‑1101
Legislative declaration 10‑3‑1102
Definitions 10‑3‑1103
Unfair methods of competition - unfair or deceptive acts or practices - prohibited 10‑3‑1104
Unfair methods of competition - unfair or deceptive practices 10‑3‑1104.5
HIV testing - legislative declaration - definitions - requirements for testing - limitations on disclosure of test results - penalty 10‑3‑1104.6
Genetic information - limitations on disclosure of information - liability - definitions - legislative declaration 10‑3‑1104.7
Genetic testing - legislative declaration - definitions - limitations on disclosure of information - liability 10‑3‑1104.8
Domestic abuse discrimination - prohibited 10‑3‑1104.9
Insurers’ use of external consumer data and information sources, algorithms, and predictive models - unfair discrimination prohibited - rules - stakeholder process required - investigations - definitions - repeal 10‑3‑1105
Favored agent or insurer - coercion of debtors 10‑3‑1106
Power of commissioner 10‑3‑1107
Hearings 10‑3‑1108
Orders 10‑3‑1109
Penalty for violation of cease-and-desist orders 10‑3‑1110
Rules 10‑3‑1111
Provisions of part 11 additional to existing law 10‑3‑1112
Immunity from prosecution 10‑3‑1113
Information to trier of fact in civil actions 10‑3‑1114
Construction of part 11 10‑3‑1115
Improper denial of claims - prohibited - definitions - severability 10‑3‑1116
Remedies for unreasonable delay or denial of benefits - required contract provision - frivolous actions - severability - definition - rules 10‑3‑1117
Required disclosures - liability - definition 10‑3‑1118
Failure-to-cooperate defense 10‑3‑1119
Policy documents - language consistent with advertisement for product - definitions 10‑3‑1201
Legislative declaration 10‑3‑1202
Definitions 10‑3‑1203
Book-entry system 10‑3‑1301
Short title 10‑3‑1302
Legislative declaration 10‑3‑1303
Definitions 10‑3‑1304
Identification of parts 10‑3‑1305
Disclosure 10‑3‑1306
Unfair and deceptive acts 10‑3‑1307
Liability 10‑3‑1401
Short title 10‑3‑1402
Purpose 10‑3‑1403
Authority of commissioner 10‑3‑1501
Purpose and scope - applicability - legislative declaration 10‑3‑1502
Definitions 10‑3‑1503
Risk management framework 10‑3‑1504
ORSA requirement 10‑3‑1505
ORSA summary report 10‑3‑1506
Exemption 10‑3‑1507
Contents of ORSA summary report 10‑3‑1508
Confidentiality 10‑3‑1509
Sanctions 10‑3‑1510
Rules 10‑3‑1511
Effective date 10‑3‑1601
Purpose and scope - applicability - legislative declaration 10‑3‑1602
Definitions 10‑3‑1603
Disclosure requirement 10‑3‑1604
Contents of corporate governance annual disclosure - rules 10‑3‑1605
Confidentiality 10‑3‑1606
Retention of third-party consultants - information sharing 10‑3‑1607
Sanctions 10‑3‑1608
Rules 10‑3‑1701
Definitions 10‑3‑1702
Plan of division - general requirements 10‑3‑1703
Plan of division - dividing insurer to survive division 10‑3‑1704
Plan of division - dividing insurer to not survive division 10‑3‑1705
Amending plan of division 10‑3‑1706
Abandoning plan of division 10‑3‑1707
Approval of plan of division - articles of incorporation and bylaws 10‑3‑1708
Commissioner approval of plan of division 10‑3‑1709
Confidentiality - records 10‑3‑1710
Certificate of division 10‑3‑1711
After division is effective 10‑3‑1712
Resulting insurers’ liability for allocated assets and debts 10‑3‑1713
Shareholder appraisal rights 10‑3‑1714
Rules 10‑3‑1715
Enforcement by commissioner 10‑3‑1716
Merger or consolidation effective with division
Green check means up to date. Up to date

Current through Fall 2024

§ 10-3-803.5’s source at colorado​.gov